Toxicology – Botulism

Core concept

Botulism is a life-threatening neuroparalytic illness caused by botulinum neurotoxin.

The characteristic syndrome is:

Cranial nerve palsies → symmetric descending flaccid paralysis → respiratory failure

A particularly important diagnostic clue is:

Descending paralysis with preserved sensation and usually preserved consciousness

Botulinum toxin prevents acetylcholine release from presynaptic cholinergic nerve terminals, producing skeletal-muscle and autonomic paralysis.

Causative Organisms

Botulism is usually caused by toxin produced by Clostridium botulinum, an anaerobic, spore-forming gram-positive organism.

Botulinum neurotoxin may also rarely be produced by:

• Clostridium baratii
• Clostridium butyricum

The traditional botulinum neurotoxin serotypes are:

A, B, C, D, E, F, and G

The older description of “eight strains” reflects historical toxin classification rather than the modern conventional seven-serotype A–G system.

Forms of Botulism

Major clinical forms include:

1. Foodborne botulism

Preformed toxin is ingested in contaminated food.

Classic sources include:

• Improperly home-canned food
• Fermented or preserved foods
• Improperly processed foods
• Certain preserved fish products

Several people who shared the same food may become ill.

2. Infant botulism

Spores are ingested → intestinal colonization → toxin produced within the intestine.

Typical early manifestations include:

• Constipation
• Poor feeding
• Weak cry
• Loss of head control
• Hypotonia

Infants can subsequently develop bulbar weakness and respiratory failure.

3. Wound botulism

Spores contaminate a wound and produce toxin locally.

It is particularly associated with:

• Injection drug use
• Contaminated traumatic wounds

Neurologic manifestations resemble foodborne botulism, but GI prodromal symptoms are usually absent.

4. Adult intestinal colonization botulism

Rarely, the organism colonizes the adult intestine and produces toxin in vivo.

Risk factors may include:

• Altered gastrointestinal anatomy
• Intestinal disease
• Altered intestinal flora

5. Iatrogenic botulism

Can occur after excessive systemic exposure to therapeutic or cosmetic botulinum toxin injections.

6. Inhalational botulism

Extremely rare naturally, but possible with laboratory or intentional aerosol exposure.

Infant Botulism and Honey

Children younger than 12 months should not be given honey, because honey can contain C. botulinum spores.

This includes avoiding honey added to:

• Food
• Water
• Formula
• Pacifiers

Pathophysiology

Botulinum neurotoxin binds irreversibly to presynaptic cholinergic nerve terminals.

It enters the nerve terminal and interferes with the SNARE proteins necessary for acetylcholine-containing vesicles to fuse with the presynaptic membrane.

Therefore:

Botulinum toxin → prevents acetylcholine release → neuromuscular transmission failure → flaccid paralysis

It affects:

• Neuromuscular junctions
• Parasympathetic autonomic terminals
• Other cholinergic autonomic synapses

Recovery requires formation and restoration of functional nerve terminals, explaining why weakness can persist for weeks to months.

Clinical Features

Classic Neurologic Pattern

The classic sequence is:

Cranial nerves first → bulbar muscles → neck/upper extremities → trunk/lower extremities → respiratory muscles

The paralysis is:

• Symmetric
• Descending
• Flaccid
• Generally without sensory loss

CDC emphasizes that botulism typically begins with prominent cranial nerve dysfunction and progresses downward.

Cranial Nerve Findings

Common early manifestations include:

• Diplopia
• Blurred vision
• Ptosis
• Ophthalmoplegia
• Dysarthria
• Dysphonia
• Dysphagia
• Facial weakness

Pupils may become:

• Dilated
• Sluggishly reactive
• Occasionally fixed

Bulbar Dysfunction

Bulbar weakness may cause:

• Difficulty swallowing
• Nasal speech
• Weak gag
• Drooling
• Poor airway protection
• Aspiration

Bulbar weakness is an important warning sign for impending respiratory deterioration.

Respiratory

Progressive respiratory-muscle paralysis may cause:

• Reduced tidal volume
• Dyspnea
• Weak cough
• Inability to clear secretions
• Hypercapnia
• Respiratory failure

Hypoxemia may be a late finding.

Therefore, normal oxygen saturation does not guarantee adequate respiratory muscle function early in the disease.

Autonomic Findings

Botulinum toxin can cause autonomic dysfunction including:

• Dry mouth
• Dry eyes
• Constipation
• Urinary retention
• Ileus
• Orthostatic hypotension
• Blood-pressure variability
• Tachycardia or bradycardia

Mental Status

A classic feature is:

The patient may be profoundly weak or paralyzed while remaining awake and cognitively intact.

This can cause considerable anxiety, particularly in mechanically ventilated patients.

CDC recommends establishing communication systems and providing psychological support for these patients.

Foodborne Botulism

Incubation

Symptoms commonly begin approximately:

12–36 hours after ingestion

but onset can range from several hours to several days depending on toxin dose and other factors.

Gastrointestinal Prodrome

Possible early symptoms include:

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea

These are followed by neurologic manifestations.

Not every patient develops prominent GI symptoms.

Infant Botulism

Think of infant botulism when an infant develops:

Constipation + poor feeding + weak cry + hypotonia

Other manifestations include:

• Ptosis
• Sluggish pupils
• Flattened facial expression
• Weak suck
• Weak gag
• Loss of head control
• Generalized “floppiness”
• Respiratory difficulty

Wound Botulism

Clinical manifestations are similar to foodborne disease but typically:

No gastrointestinal prodrome

Examine carefully for:

• Injection sites
• Abscesses
• Necrotic wounds

The external appearance of the wound does not reliably predict whether toxin is being produced.

Diagnosis

Botulism is initially a clinical diagnosis.

Do not wait for laboratory confirmation before treating a patient with clinically suspected progressive botulism.

CDC emphasizes that delays in antitoxin administration can worsen outcomes.

Laboratory Confirmation

Depending on the clinical form, public-health laboratories may test:

• Serum
• Stool
• Gastric contents
• Wound specimens
• Suspected food

Confirmation can involve:

• Detection of botulinum neurotoxin
• Isolation of a botulinum toxin-producing Clostridium species

Whenever possible, serum should be collected before antitoxin, but specimen collection must not delay treatment.

Infant Botulism Testing

For infant botulism, stool is the preferred diagnostic specimen for toxin testing and culture.

Treatment with BabyBIG should not be delayed while waiting for the result.

Differential Diagnosis

Important mimics include:

Neuromuscular

• Guillain-Barré syndrome
• Miller Fisher syndrome
• Myasthenia gravis
• Lambert-Eaton myasthenic syndrome
• Tick paralysis

Toxicologic

• Organophosphate poisoning
• Paralytic shellfish poisoning
• Certain snake envenomations
• Magnesium toxicity
• Neuromuscular-blocking drugs

Neurologic

• Brainstem stroke
• CNS infection
• Poliomyelitis

Botulism is distinguished particularly by:

Prominent cranial neuropathies + symmetric descending paralysis + absence of sensory deficits.

Electrodiagnostic Testing

EMG and nerve-conduction studies can support the diagnosis.

Possible findings include:

• Low-amplitude compound muscle action potentials
• Incremental response with high-frequency repetitive nerve stimulation
• Presynaptic neuromuscular-junction abnormalities

However, electrophysiologic findings may be absent or nonspecific early in disease.

Respiratory Monitoring

This is one of the most important aspects of management.

Monitor serially:

• Respiratory rate
• Work of breathing
• Bulbar function
• Forced vital capacity
• Inspiratory strength
• Expiratory strength
• End-tidal CO₂ when available

Serial measurements are more valuable than a single measurement.

Concerning Respiratory Values

Because specific botulism thresholds are not well validated, CDC notes that thresholds used for other neuromuscular disorders may help guide decisions.

Concerning findings include approximately:

• FVC <20 mL/kg
• Maximum inspiratory pressure / NIF weaker than approximately −30 cm H₂O
• Maximum expiratory pressure <40 cm H₂O

These values should not be used in isolation; worsening bulbar weakness or clinical respiratory fatigue may justify earlier intubation.

Important Pitfall

Do not wait for:

• Hypoxemia
• Severe hypercapnia
• Respiratory arrest

before intubation.

Pulse oximetry and ABG abnormalities can occur late in neuromuscular respiratory failure.

Treatment

1. Airway and Ventilation

Management begins with meticulous assessment of:

• Airway protection
• Swallowing ability
• Respiratory muscle strength

Early endotracheal intubation and mechanical ventilation may be lifesaving.

Some patients require ventilatory support for weeks to months while neuromuscular function recovers.

2. Botulinum Antitoxin

For non-infant botulism, the current U.S. product is:

Botulism Antitoxin Heptavalent (BAT)

It contains antibodies against toxin types:

A, B, C, D, E, F, and G

and is equine-derived.

Mechanism

Antitoxin:

Binds circulating unbound toxin → prevents toxin from reaching additional nerve terminals

It does not remove toxin already internalized into nerve terminals.

Therefore:

Antitoxin stops progression; it does not immediately reverse established paralysis.

Timing

Give antitoxin as early as possible when botulism is clinically suspected.

The greatest benefit occurs when treatment begins within the first 1–2 days, but patients with continuing progression may still benefit later.

Do not wait for laboratory confirmation.

Adult BAT Dose

Current U.S. labeling specifies:

1 vial IV for adults ≥17 years

Pediatric dosing is weight/age based.

Antitoxin Adverse Effects

Because BAT is equine-derived, monitor for:

• Infusion reactions
• Anaphylaxis
• Delayed serum sickness

Routine skin testing before BAT administration is not recommended by current CDC guidance.

Infant Botulism – BabyBIG

Infant botulism is treated differently.

The preferred specific therapy in the United States is:

BabyBIG® — Botulism Immune Globulin Intravenous (Human)

It contains human antibodies against botulinum toxin types A and B and should be administered promptly when the clinical diagnosis is supported.

Treatment should not wait for laboratory confirmation.

Important 2026 Dosing Update

The historical BabyBIG label lists 50 mg/kg.

However, in September 2026, FDA issued a specific dosage change for BabyBIG Lot 8 because that lot has higher antibody titers:

20 mg/kg (0.4 mL/kg) IV once

for Lot 8, superseding the older 50 mg/kg instruction for that lot.

Therefore:

Use the current lot-specific BabyBIG dosing instructions rather than relying on older textbook doses.

Wound Botulism

Management includes:

Antitoxin

Administer BAT promptly when wound botulism is suspected.

Surgical treatment

Debridement of infected or devitalized tissue helps eliminate the source of ongoing toxin production.

Antibiotics

Antibiotics may be appropriate as part of wound management, but antitoxin and debridement remain fundamental.

CDC notes that routine antimicrobials do not treat the circulating neurotoxin itself.

Gastrointestinal Decontamination

The older source recommends:

• Gastric lavage
• Activated charcoal
• Whole-bowel irrigation

These are not routine modern treatments for botulism.

CDC notes that there are no human data demonstrating benefit from activated charcoal, while patients with bulbar weakness are at significant risk of aspiration. There is also no established benefit from polyethylene-glycol bowel-cleansing therapy.

Therefore, treatment should prioritize:

Antitoxin + airway protection + respiratory monitoring

rather than aggressive GI decontamination.

Medications to Use With Caution

Aminoglycosides

Aminoglycosides can impair neuromuscular transmission and may worsen paralysis.

Examples include:

• Gentamicin
• Amikacin
• Tobramycin

They should be used only after careful consideration when clinically necessary.

Magnesium

Magnesium suppresses presynaptic acetylcholine release and may aggravate neuromuscular weakness.

Use cautiously.

Other Agents

CDC also recommends careful consideration with:

• Clindamycin
• Tetracyclines
• Neuromuscular-blocking drugs
• Other medications that impair neuromuscular transmission

Supportive ICU Care

Patients may require prolonged intensive care.

Important measures include:

• Mechanical ventilation
• Aspiration precautions
• Enteral nutritional support
• DVT prophylaxis
• Pressure-injury prevention
• Bladder care
• Bowel management
• Eye lubrication for impaired blinking/dry eyes
• Physical and occupational rehabilitation

CDC specifically emphasizes preventing complications associated with prolonged paralysis and ventilation.

Public Health Management

Botulism is a public-health emergency because:

• Contaminated food may expose multiple people
• Rapid access to antitoxin is required
• Public-health laboratories perform specialized diagnostic testing

In the United States, suspected cases should be reported immediately to the appropriate health department, which coordinates consultation, testing, and antitoxin through CDC.

Admission

All patients with suspected symptomatic botulism should be managed in a hospital capable of close neurologic and respiratory monitoring.

Patients with:

• Bulbar dysfunction
• Progressive weakness
• Respiratory abnormalities

generally require ICU-level observation or care. CDC recommends hospital admission for suspected cases under conventional standards of care.

Prognosis

With modern critical care and antitoxin, mortality has fallen dramatically.

Current mortality is <5%, compared with much higher historical rates.

However, recovery may be prolonged because damaged neuromuscular junctions need time to regenerate.

Patients may require:

• Weeks to months of ventilation
• Rehabilitation
• Nutritional support

Persistent symptoms may include:

• Fatigue
• Weakness
• Exertional dyspnea

for months or occasionally longer.

Important Pitfalls

1. Waiting for laboratory confirmation

Do not delay antitoxin while waiting for toxin assays or cultures.

Clinical suspicion is sufficient to initiate the public-health consultation and treatment process.

2. Waiting for hypoxemia before intubating

Respiratory-muscle failure can be advanced before oxygen saturation falls.

Monitor:

• FVC
• Inspiratory strength
• Bulbar function
• Clinical respiratory effort

3. Assuming antitoxin reverses established paralysis

Antitoxin only neutralizes circulating, unbound toxin.

Established weakness resolves gradually through neuronal recovery.

4. Missing the cranial nerve pattern

Early symptoms such as:

• Diplopia
• Ptosis
• Dysphagia
• Dysarthria

may precede obvious limb weakness.

5. Mistaking botulism for Guillain-Barré syndrome

Botulism characteristically produces:

Cranial nerves first + descending symmetric paralysis + no sensory loss

6. Giving unnecessary magnesium or neuromuscular-blocking drugs

These may worsen weakness.

7. Using the old antitoxin regimen

The historical mono-, bi-, and trivalent antitoxins have been replaced in the United States by:

Heptavalent BAT (A–G) for non-infant botulism.

8. Using the old BabyBIG dose without checking the current lot

As of September 2026, FDA specifies 20 mg/kg for BabyBIG Lot 8, rather than the older 50 mg/kg label dose.

9. Missing infant botulism

Remember:

Constipation may be the first symptom.

Followed by:

• Poor feeding
• Weak cry
• Hypotonia
• Loss of head control

10. Giving honey to an infant

No honey before 12 months of age.

High-Yield Toxicology Pearls

Botulism = cranial nerve palsies + symmetric descending flaccid paralysis

Think:

Diplopia/ptosis → dysarthria/dysphagia → descending weakness → respiratory failure

Key points:

• Mechanism: presynaptic inhibition of acetylcholine release
• Sensation is generally preserved
• Mental status is usually preserved
• Foodborne botulism = preformed toxin ingestion
• Infant botulism = intestinal colonization and toxin production
• Wound botulism = toxin production in contaminated tissue
• Infant clue: constipation + poor feeding + floppy baby
• Do not give honey before 12 months
• Diagnosis is initially clinical
• Do not wait for laboratory confirmation
• Closely monitor respiratory and bulbar function
• Normal pulse oximetry does not exclude impending ventilatory failure
• Main specific treatment for non-infant disease: heptavalent BAT
• BAT prevents progression but does not reverse existing paralysis
• Infant botulism: BabyBIG
• Current BabyBIG Lot 8 dosing: 20 mg/kg IV once
• Wound botulism also requires source control/debridement
• Avoid or use caution with drugs that impair neuromuscular transmission, particularly aminoglycosides and magnesium
• Activated charcoal and bowel irrigation have no established routine benefit
• Respiratory support is the most important life-saving supportive treatment
• Recovery commonly takes weeks to months